Entries by Hannah Thomson

American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2020

OracleBio will be taking part in the 2020 Virtual Annual Meeting of the American Society for Clinical Oncology (ASCO), which takes place virtually from the 29th May – 2nd June. OracleBio offers a range of digital pathology services to support clinical oncology R&D. Our services have wide application in clinical research including patient stratification, drug […]

2019 – A Year in Review

2019 was a big year for OracleBio in many aspects, with new software, new team members and new clients. In our annual year in review blog, we share our key highlights and insights into our activity from the past year. Deep Learning As expected, artificial intelligence and the use of deep learning in image analysis […]

Dr James Going joins OracleBio as Senior Pathologist

OracleBio is pleased to welcome Dr James Going, who has recently joined the team as Senior Pathologist. James brings a huge amount of expertise to the role with over 39 years of pathology experience. Currently working as a Consultant Clinical Pathologist in the NHS, he has a wide and deep knowledge of diagnostic histopathology with […]

Applying deep learning classification for tumor identification across immunohistochemical markers on serial sections to eliminate the need for image co-registration

OracleBio presented a poster at the Society for Immunotherapy of Cancer Annual Meeting 2019 on the 6th – 10th November. The poster is entitled ‘Applying deep learning classification for tumor identification across immunohistochemical markers on serial sections to eliminate the need for image co-registration’ and was presented on Saturday November 9th 2019, 7:00 AM – 8:30 […]

Labs Explorer interviews OracleBio’s Dr Lorcan Sherry

Dr Lorcan Sherry, OracleBio’s Chief Scientific Officer, was recently interviewed by Labs Explorer, an online R&D marketplace that offers a platform for researchers to search for R&D partners, increase visibility and gain financing. In the interview, Lorcan talks about OracleBio’s history and mission as a leading quantitative digital pathology CRO. He also discusses the challenges […]

Keith Bowers joins OracleBio as Senior Business Development Manager

In line with OracleBio’s vision to drive the adoption and application of digital pathology in R&D, we are thrilled to welcome Dr Keith Bowers as the new Senior Business Development Manager. Applying his 25 years of experience in both scientific and commercial roles within the pharmaceutical industry, Keith joins us to accelerate the company’s growth, […]

6th Digital Pathology & AI Congress 2019

OracleBio will be attending the 6th Digital Pathology & AI Congress, which takes place from the 5th to 6th of December 2019 in London, UK. OracleBio will be exhibiting at Booth 36 throughout the meeting. OracleBio is a highly specialised image analysis CRO (contract research organization) providing high precision, quantitative, digital image analysis services to support […]

Case Study: Clinical R&D

OracleBio contributed to a Clinical R&D program for a global oncology company focused on precision oncology. By utilising multiplex immunofluorescence (IF) and quantitative digital pathology, we supported the researchers in understanding lymphocyte composition within NSCLC tissue by providing quantitative analysis of LAG-3 +ve TIL subsets within tumour microenvironment and determining ratios of dual and triple […]

Case Study: Pre-clinical R&D

OracleBio contributed to a Pre-clinical R&D program for a UK-based drug discovery company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology. By utilising Immunohistochemistry (IHC) and quantitative digital pathology, we supported the data-driven decision-making process for proof of mechanism studies by providing quantitative and reproducible tissue-based evidence […]